Singapore-based Hyphens Pharma has announced its exclusive acquisition of the rights to register and commercialize Amenalief® Tab 200mg, a shingles treatment developed by Japan-based pharmaceutical company Maruho, across 10 ASEAN countries.
Maruho’s shingles drug, Amenalief® Tab 200mg, obtained approval and was introduced to the Japanese market in 2017. Now, with this recent agreement, Hyphens Pharma aims to bring this innovative treatment to Southeast Asia, where the prevalence of Varicella-Zoster Virus type 2 (VZV2) among adults over 50 is significant, posing a heightened risk for shingles development.
Highlighting the distinctive features of Amenalief®, Hyphens Pharma underscores its novel mechanism of action, targeting the helicase-primase complex to impede VZV proliferation effectively. Notably, the drug’s once-daily administration for seven days stands out against conventional therapies, which typically require three to five dosages per day. Additionally, unlike other oral treatments, Amenalief® eliminates concerns regarding dosage adjustment in older patients with renal impairment, addressing a common medical consideration in this demographic.
This strategic move by Hyphens Pharma signals a significant advancement in addressing shingles treatment and underscores the company’s commitment to delivering innovative solutions to healthcare challenges across the ASEAN region.
Related Topics:
